{"title":"Switching from first or second generation EGFR-TKI to osimertinib in <i>EGFR</i> mutation-positive NSCLC.","authors":"Fumio Imamura, Takako Inoue, Kei Kunimasa, Aki Kubota, Hanako Kuhara, Motohiro Tamiya, Kazumi Nishino, Madoka Kimura, Kika Kuno, Hayato Kawachi, Toru Kumagai","doi":"10.2217/lmt-2020-0005","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for <i>EGFR</i> mutation-positive NSCLC.</p><p><strong>Materials & methods: </strong>Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for <i>T790M</i>-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.</p><p><strong>Results: </strong>Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.</p><p><strong>Conclusion: </strong>Switch use of osimertinib seemed to produce improved efficacy for patients with activating <i>EGFR</i> mutations, because of the lack of patient selection via <i>T790M</i>.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2020-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/lmt-2020-0005","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2020-0005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4
Abstract
Aim: We evaluated the efficacy of a novel switch protocol for EGFR-TKIs for EGFR mutation-positive NSCLC.
Materials & methods: Clinical records were collected from the patients who had received one of two sequential combination strategies of EGFR-TKIs: Salvage use of osimertinib for T790M-mediated acquired resistance to an prior EGFR-TKI or switch use of osimertinib where an EGFR-TKI was switched to osimertinib before disease progression.
Results: Progression-free survival of osimertinib and time from the start of treatment until progression to osimertinib was comparable between the salvage use and switch use of osimertinib.
Conclusion: Switch use of osimertinib seemed to produce improved efficacy for patients with activating EGFR mutations, because of the lack of patient selection via T790M.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
